Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.190
-0.050 (-2.23%)
At close: Apr 28, 2026, 4:00 PM EDT
2.174
-0.016 (-0.75%)
After-hours: Apr 28, 2026, 7:44 PM EDT
Daré Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1.03 | 0.01 | 2.81 | 10 | - | |
| Revenue Growth (YoY) | 10429.36% | -99.65% | -71.92% | - | - | |
| Cost of Revenue | 0.3 | - | 21.64 | 30.14 | 0.1 | |
| Gross Profit | 0.73 | 0.01 | -18.83 | -20.14 | -0.1 | |
| Selling, General & Admin | 8.76 | 9.16 | 11.91 | 11.24 | 8.35 | |
| Research & Development | 5.52 | 14.31 | - | - | 30.62 | |
| Operating Expenses | 14.29 | 23.46 | 11.91 | 11.24 | 38.97 | |
| Operating Income | -13.55 | -23.45 | -30.74 | -31.39 | -39.07 | |
| Other Non Operating Income (Expenses) | 0.15 | 20 | 0.78 | 0.44 | 0 | |
| EBT Excluding Unusual Items | -13.4 | -3.45 | -29.96 | -30.95 | -39.07 | |
| Gain (Loss) on Sale of Assets | - | -0.6 | - | - | - | |
| Other Unusual Items | - | - | -0.4 | - | 0.37 | |
| Pretax Income | -13.4 | -4.05 | -30.16 | -30.95 | -38.7 | |
| Net Income | -13.4 | -4.05 | -30.16 | -30.95 | -38.7 | |
| Net Income to Common | -13.4 | -4.05 | -30.16 | -30.95 | -38.7 | |
| Shares Outstanding (Basic) | 11 | 8 | 7 | 7 | 5 | |
| Shares Outstanding (Diluted) | 11 | 8 | 7 | 7 | 5 | |
| Shares Change (YoY) | 31.55% | 16.80% | 3.23% | 38.29% | 103.23% | |
| EPS (Basic) | -1.20 | -0.48 | -4.15 | -4.39 | -7.59 | |
| EPS (Diluted) | -1.20 | -0.48 | -4.15 | -4.39 | -7.59 | |
| Free Cash Flow | -10.27 | 4.9 | -39.49 | -18.15 | -28.78 | |
| Free Cash Flow Per Share | -0.92 | 0.58 | -5.43 | -2.58 | -5.65 | |
| Gross Margin | 71.29% | 100.00% | - | -201.42% | - | |
| Operating Margin | -1315.51% | -239692.20% | -1094.77% | -313.86% | - | |
| Profit Margin | -1300.66% | -41430.90% | -1074.17% | -309.48% | - | |
| Free Cash Flow Margin | -997.01% | 50086.97% | -1406.26% | -181.52% | - | |
| EBITDA | -11.92 | -23.41 | -30.7 | -31.36 | -39.04 | |
| D&A For EBITDA | 1.63 | 0.04 | 0.04 | 0.02 | 0.03 | |
| EBIT | -13.55 | -23.45 | -30.74 | -31.39 | -39.07 | |
| Revenue as Reported | 1.03 | 0.01 | 2.81 | 10 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.